AI in clinical trials targets operational bottlenecks in drug development

Artificial intelligence is increasingly being applied to clinical trials to address operational inefficiencies, particularly in protocol design, site selection, patient recruitment, and data cleaning. While AI is compressing discovery timelines, industry leaders note that gaps in testing, data, and community access remain significant hurdles to patient benefit.

In the clinical trial sector, patient recruitment is a primary cause of delay. Language models are being utilized to match unstructured medical records against eligibility criteria to accelerate this process. The AI-based clinical trials solution provider market is projected to grow from approximately $3.5 billion in 2026 to $7.8 billion by 2030.

Despite these technological advancements, the failure rate for drugs entering clinical trials remains at roughly 90 percent. Regulators now require documented credibility for any AI influencing regulatory decisions, emphasizing that validation must be a core component of the submission process rather than a separate phase.